253 results on '"Yauch, Robert L."'
Search Results
2. Smarca2 genetic ablation is phenotypically benign in a safety assessment of tamoxifen-inducible conditional knockout rats
3. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
4. Androgen receptor-negative prostate cancer is vulnerable to SWI/SNF-targeting degrader molecules
5. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
6. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients
7. Supplementary Figure 1 from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
8. Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
9. Supplementary Figure 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
10. Supplementary Figure 3 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
11. Supplementary Figure 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
12. Supplementary Dataset 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
13. Data from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
14. Data from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
15. Supplementary Figure 4 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
16. Supplementary Figure 2 from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
17. Supplementary Figure 7 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
18. Supplementary Methods and Figure Legend from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
19. Supplementary Figure 6 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
20. Supplementary Figure 5 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
21. Supplementary Figure 8 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
22. Supplementary Tables 1 - 7 from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
23. Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
24. Supplementary Figures 1 - 9 from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
25. Supplementary Table 1 from A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
26. Supplementary Figure 2 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
27. Supplementary Table 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
28. Supplementary Figure 5 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
29. CCR Translation for This Article from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
30. Supplementary Methods from Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
31. Supplementary Table Legend from A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
32. Supplementary Methods and Tables from Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors
33. Supplementary Figure 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
34. Supplementary Figure 4 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
35. Supplementary Methods, Figures 1-9, Tables 1-4 from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
36. Supplementary Figure 1 from Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors
37. Supplementary Figure 1 from Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation
38. Supplementary Figure 3 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
39. Supplementary Figure Legend from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
40. Supplementary Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
41. Data from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
42. Supplemental Movie 3 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
43. Supplemental Movie 1 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
44. Supplemental Movie 2 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
45. Supplementary Methods, Figure Legends 1-6 from Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
46. Supplemental Dataset 1 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
47. Supplemental Figures S1-S11, Datasets 1-3 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
48. Supplementary Table 1 from Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
49. Supplemental Dataset 2 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
50. Supplemental Dataset 3 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.